Multicharge beta-cyclodextrin supramolecular assembly for ATP capture and drug release

Water-soluble seven hexylimidazolium modified amphiphilic cyclodextrin (AMCD) selectively combined with ATP to form a stable 1 : 1 inclusion complex AMCD * ATP, which was mainly driven by entropy changes. As a result, due to the presence of the hydrophobic cavity of AMCD, the hydrolysis of ATP was effectively inhibited. The hydrophobic anticancer drug chlorambucil was loaded in an assembly of adamantyl-grafted hyaluronic acid and an amphiphilic beta-cyclodextrin bearing seven hexylimidazolium units. The assembly could specifically target cancer cells and respond to hyaluronidase thus releasing the anticancer drug chlorambucil. Moreover, the AMCD and ATP formed a host–guest inclusion complex, which cut off the energy supply of cancer cells and thus could effectively alleviate the multidrug resistance of cancer cells. CCK8 analysis showed that in the presence of AMCD, the efficacy of the anti-cancer drug chlorambucil has been effectively improved. The results of this study indicated that the amphiphilic cyclodextrin can overcome the multidrug resistance in cancer treatment to some extent and is expected to become a synergistic carrier for enhanced chemotherapy,

C Chen, Y Chen, X Dai, J Li, S Jia, S Wang, Y Liu (2021) Multicharge b-cyclodextrin supramolecular assembly for ATP capture and drug release. Chemical Communications DOI: 10.1039/d1cc00292a